LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 72

Search options

  1. Article: Blood-Derived Liquid Biopsies Using Foundation One

    Cahn, Fanny / Revon-Riviere, Gabriel / Min, Victoria / Rome, Angélique / Filaine, Pauline / Pelletier, Annick / Abed, Sylvie / Gentet, Jean-Claude / Verschuur, Arnauld / André, Nicolas

    Cancers

    2022  Volume 14, Issue 11

    Abstract: Precision oncology requires tumor molecular profiling to identify actionable targets. Tumor biopsies are considered as the gold standard, but their indications are limited by the burden of procedures in children. Blood-derived liquid biopsy (LB) is a ... ...

    Abstract Precision oncology requires tumor molecular profiling to identify actionable targets. Tumor biopsies are considered as the gold standard, but their indications are limited by the burden of procedures in children. Blood-derived liquid biopsy (LB) is a potential alternative that is not yet documented in real-world settings, especially in pediatric oncology. We performed a retrospective analysis of children and teenagers with a relapsing or refractory disease, upon whom LB was performed using the Foundation One® liquid CDx from 1 January 2020 to 31 December 2021 in a single center. Forty-five patients (27 boys) were included, with a median age of 9 years of age (range: 1.5-17 years old). Underlying malignancies were neuroblastoma (12 patients), bone sarcoma (12), soft tissue sarcoma (9), brain tumors (7), and miscellaneous tumors (5). Forty-three patients had metastatic disease. Six patients had more than one biopsy because of a failure in first LB. Median time to obtain results was 13 days. Overall, analysis was successful for 33/45 patients. Eight patients did not present any molecular abnormalities. Molecular alterations were identified in 25 samples with a mean of 2.1 alterations per sample. The most common alterations concerned TP53 (7 pts), EWS-FLI1 (5), ALK (3), MYC (3), and CREBBP (2). TMB was low in all cases. Six patients received treatment based on the results from LB analysis and all were treated off-trial. Three additional patients were included in early phase clinical trials. Mean duration of treatment was 85 days, with one patient with stable disease after eight months. Molecular profiling using Foundation One® Liquid CDx was feasible in pediatric patients with high-risk solid tumors and lead to identification of targetable mutations in a subset of patients.
    Language English
    Publishing date 2022-06-02
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers14112774
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Metronomic Maintenance With Weekly Vinblastine After Induction With Bevacizumab-Irinotecan in Children With Low-grade Glioma Prevents Early Relapse.

    Roux, Clémence / Revon-Rivière, Gabriel / Gentet, Jean Claude / Verschuur, Arnauld / Scavarda, Didier / Saultier, Paul / Appay, Romain / Padovani, Laetitia / André, Nicolas

    Journal of pediatric hematology/oncology

    2020  Volume 43, Issue 5, Page(s) e630–e634

    Abstract: Background: Pediatric low-grade glioma (pLGG) represents the most common brain tumor in childhood. Previous studies have reported that a therapeutic strategy on the basis of the association of bevacizumab alone (B) or in combination with irinotecan (BI) ...

    Abstract Background: Pediatric low-grade glioma (pLGG) represents the most common brain tumor in childhood. Previous studies have reported that a therapeutic strategy on the basis of the association of bevacizumab alone (B) or in combination with irinotecan (BI) could produce rapid tumor response and clinical improvement in children with pLGG. Nevertheless, a majority of patients relapses shortly (median, 5 mo) after stopping B or BI treatment. We proposed metronomic maintenance with weekly vinblastine added after a 6 months induction of B/BI to prevent early relapse.
    Patients and methods: Monocentric retrospective analysis of a patient with pLGG treated with B or BI for 6 months followed by a 12-month maintenance with weekly vinblastine (6 mg/m²) from October 2012 to September 2019 in a single institution.
    Results: In total, 18 patients (7 males and 11 females) were identified. Because of progression during the B or BI induction 2/18 children were excluded. In total, 16 patients were analyzed with a median age of 10 years (range, 4 to 16 y). A total of 13 patients received BI and 3 patients received B alone. The mean duration of induction was 6.2 months (range, 2 to 12 mo). After induction 5/16 patients had a partial radiologic response, 11/16 patients had stable disease. All patients started maintenance (median duration, 12 mo; range, 3 to 12 mo). With a median follow-up of 3.9 years after the end of B or BI (range, 11 mo to 7.2 y), 15/16 patients were alive and 9/16 patients were progression-free. Seven of 16 children progressed with a median time to progression of 23 months (ranges, 5 to 39 mo). Three of 16 (18%) children progressed during vinblastine maintenance and 4/16 (25%) patients after the end of maintenance. After the total duration of treatment, clinical improvement was noted in 4 patients, 9 patients had stable symptoms, and only 3 patients progressed. One and 2-year event-free survival were, respectively, 81.2% and 56.2%. Two-year overall survival was 93.7%.
    Conclusions: We report here, the potential benefit and the improvement of progression-free survival by adding metronomic maintenance with weekly vinblastine after initial induction with B or BI in children with low-grade glioma.
    MeSH term(s) Administration, Metronomic ; Adolescent ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bevacizumab/administration & dosage ; Bevacizumab/therapeutic use ; Brain Neoplasms/drug therapy ; Brain Neoplasms/pathology ; Child ; Child, Preschool ; Female ; Glioma/drug therapy ; Glioma/pathology ; Humans ; Irinotecan/administration & dosage ; Irinotecan/therapeutic use ; Male ; Neoplasm Recurrence, Local/pathology ; Neoplasm Recurrence, Local/prevention & control ; Retrospective Studies ; Vinblastine/administration & dosage ; Vinblastine/therapeutic use
    Chemical Substances Antineoplastic Agents ; Bevacizumab (2S9ZZM9Q9V) ; Vinblastine (5V9KLZ54CY) ; Irinotecan (7673326042)
    Language English
    Publishing date 2020-11-23
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1231152-2
    ISSN 1536-3678 ; 1077-4114 ; 0192-8562
    ISSN (online) 1536-3678
    ISSN 1077-4114 ; 0192-8562
    DOI 10.1097/MPH.0000000000002002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1537: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: A Randomized Trial of Physical Activity in Children and Adolescents with Cancer.

    Saultier, Paul / Vallet, Clothilde / Sotteau, Frédéric / Hamidou, Zeinab / Gentet, Jean-Claude / Barlogis, Vincent / Curtillet, Catherine / Verschuur, Arnauld / Revon-Riviere, Gabriel / Galambrun, Claire / Chambost, Hervé / Auquier, Pascal / Michel, Gérard / André, Nicolas

    Cancers

    2021  Volume 13, Issue 1

    Abstract: Background: to evaluate the safety and efficacy of a physical activity program (PAP) in children and adolescents with cancer.: Methods: children and adolescents with cancer were randomly assigned in a 1:1 ratio to the six-month PAP (intervention ... ...

    Abstract Background: to evaluate the safety and efficacy of a physical activity program (PAP) in children and adolescents with cancer.
    Methods: children and adolescents with cancer were randomly assigned in a 1:1 ratio to the six-month PAP (intervention group) or to the control group. The first evaluation was performed at the end of the PAP (T0 + 6 mo). At T0 + 6 mo, both groups received the six-month PAP with a second evaluation at T0 + 12 mo. The primary outcome was the evolution of exercise capacity measured using the six-minute walk test (6 MWT) at T0 + 6 mo. Secondary outcomes included PAP safety and changes in other physical functions, self-esteem, and quality-of-life parameters.
    Results: The trial involved 80 children and adolescents (age range 5.0-18.4 years), of whom 41 were assigned to the interventional group and 39 to the control group. Underlying malignancies were leukemia (39%) and a broad range of solid tumors (61%). No adverse events occurred. At T0 + 6 mo, the evolution of the 6 MWT distance (±SEM) was improved in the intervention group vs. the control group (86 ± 12 m vs. 32 ± 6 m,
    Conclusion: In children and adolescents with cancer, a physical activity program is safe, improves exercise capacity, and may have physical and psychological benefits.
    Language English
    Publishing date 2021-01-02
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers13010121
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Diffusion-weighted imaging in differentiating mid-course responders to chemotherapy for long-bone osteosarcoma compared to the histologic response: an update.

    Habre, Céline / Dabadie, Alexia / Loundou, Anderson D / Banos, Jean-Bruno / Desvignes, Catherine / Pico, Harmony / Aschero, Audrey / Colavolpe, Nathalie / Seiler, Charlotte / Bouvier, Corinne / Peltier, Emilie / Gentet, Jean-Claude / Baunin, Christiane / Auquier, Pascal / Petit, Philippe

    Pediatric radiology

    2021  Volume 51, Issue 9, Page(s) 1714–1723

    Abstract: Background: Diffusion-weighted imaging (DWI) has been described to correlate with tumoural necrosis in response to preoperative chemotherapy for osteosarcoma.: Objective: To assess the accuracy of DWI in evaluating the response to neoadjuvant ... ...

    Abstract Background: Diffusion-weighted imaging (DWI) has been described to correlate with tumoural necrosis in response to preoperative chemotherapy for osteosarcoma.
    Objective: To assess the accuracy of DWI in evaluating the response to neoadjuvant chemotherapy at the mid-course treatment of long-bone osteosarcoma and in predicting survival.
    Materials and methods: We conducted a prospective single-centre study over a continuous period of 11 years. Consecutive patients younger than 20 years treated with a neoadjuvant regimen for peripheral conventional osteosarcoma were eligible for inclusion. Magnetic resonance imaging (MRI) with DWI was performed at diagnosis, and mid- and end-course chemotherapy with mean apparent diffusion coefficients (ADC) calculated at each time point. A percentage less than or equal to 10% of the viable residual tissue at the histological analysis of the surgical specimen was defined as a good responder to chemotherapy. Survival comparisons were calculated using the Kaplan-Meier method. Uni- and multivariate analyses with ADC change were performed by Cox modelling. This is an expansion and update of our previous work.
    Results: Twenty-six patients between the ages of 4.8 and 19.6 years were included, of whom 14 were good responders. At mid-course chemotherapy, good responders had significantly higher mean ADC values (P=0.046) and a higher increase in ADC (P=0.015) than poor responders. The ADC change from diagnosis to mid-course MRI did not appear to be a prognosticator of survival and did not impact survival rates of both groups.
    Conclusion: DWI at mid-course preoperative chemotherapy for osteosarcoma should be considered to evaluate the degree of histological necrosis and to predict survival. The anticipation of a response to neoadjuvant treatment by DWI may have potential implications on preoperative management.
    MeSH term(s) Adolescent ; Adult ; Bone Neoplasms/diagnostic imaging ; Bone Neoplasms/drug therapy ; Child ; Child, Preschool ; Diffusion Magnetic Resonance Imaging ; Humans ; Osteosarcoma/diagnostic imaging ; Osteosarcoma/drug therapy ; Prospective Studies ; Treatment Outcome ; Young Adult
    Language English
    Publishing date 2021-04-20
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 124459-0
    ISSN 1432-1998 ; 0301-0449
    ISSN (online) 1432-1998
    ISSN 0301-0449
    DOI 10.1007/s00247-021-05037-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 927: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Genetic variant of SRF-rearranged myofibroma with a misleading nuclear expression of STAT6 and STAT6 involvement as 3' fusion partner.

    Nihous, Hugo / Macagno, Nicolas / Baud-Massière, Jessica / Haffner, Aurélie / Jouve, Jean-Luc / Gentet, Jean-Claude / Touzery, Camille / Le Loarer, François / Bouvier, Corinne

    Virchows Archiv : an international journal of pathology

    2020  Volume 478, Issue 3, Page(s) 597–603

    Abstract: Pediatric neoplasms with a myofibroblastic differentiation are frequent in children, in particular myofibroma. Recently, a novel deep soft tissue myofibroblastic neoplasm has been described with high cellularity, a smooth muscle phenotype and SRF-RELA ... ...

    Abstract Pediatric neoplasms with a myofibroblastic differentiation are frequent in children, in particular myofibroma. Recently, a novel deep soft tissue myofibroblastic neoplasm has been described with high cellularity, a smooth muscle phenotype and SRF-RELA fusion. We report the case of a 15-year-old boy who presented with a tumor of the deep soft tissue of the arm, with overlapping histological features with the recently described SRF-RELA group of myofibromas but differing by the presence of calcifications, a novel SRF-STAT6 fusion transcript and nuclear expression of STAT6. No local recurrence nor distant metastasis was detected at the current follow-up of 29 months. The clinical relevance of this novel fusion requires further investigations.
    MeSH term(s) Adolescent ; Biomarkers, Tumor/analysis ; Biomarkers, Tumor/genetics ; Cell Nucleus/chemistry ; Cell Nucleus/genetics ; Cell Nucleus/pathology ; Gene Fusion ; Gene Rearrangement ; Humans ; Immunohistochemistry ; Male ; Myofibroma/chemistry ; Myofibroma/diagnostic imaging ; Myofibroma/genetics ; Myofibroma/pathology ; STAT6 Transcription Factor/analysis ; STAT6 Transcription Factor/genetics ; Sequence Analysis, RNA ; Serum Response Factor/genetics ; Soft Tissue Neoplasms/chemistry ; Soft Tissue Neoplasms/diagnostic imaging ; Soft Tissue Neoplasms/genetics ; Soft Tissue Neoplasms/pathology ; Upper Extremity
    Chemical Substances Biomarkers, Tumor ; SRF protein, human ; STAT6 Transcription Factor ; STAT6 protein, human ; Serum Response Factor
    Language English
    Publishing date 2020-06-11
    Publishing country Germany
    Document type Case Reports
    ZDB-ID 1184867-4
    ISSN 1432-2307 ; 0945-6317
    ISSN (online) 1432-2307
    ISSN 0945-6317
    DOI 10.1007/s00428-020-02859-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ud III Zs.10: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: High-intensity end-of-life care among children, adolescents, and young adults with cancer who die in the hospital: A population-based study from the French national hospital database.

    Revon-Rivière, Gabriel / Pauly, Vanessa / Baumstarck, Karine / Bernard, Cecile / André, Nicolas / Gentet, Jean-Claude / Seyler, Catherine / Fond, Guillaume / Orleans, Veronica / Michel, Gérard / Auquier, Pascal / Boyer, Laurent

    Cancer

    2019  Volume 125, Issue 13, Page(s) 2300–2308

    Abstract: Background: Efforts to improve the quality of end-of-life (EOL) care depend on better knowledge of the care that children, adolescents, and young adults with cancer receive, including high-intensity EOL (HI-EOL) care. The objective was to assess the ... ...

    Abstract Background: Efforts to improve the quality of end-of-life (EOL) care depend on better knowledge of the care that children, adolescents, and young adults with cancer receive, including high-intensity EOL (HI-EOL) care. The objective was to assess the rates of HI-EOL care in this population and to determine patient- and hospital-related predictors of HI-EOL from the French national hospital database.
    Methods: This was a population-based, retrospective study of a cohort of patients aged 0 to 25 years at the time of death who died at hospital as a result of cancer in France between 2014 and 2016. The primary outcome was HI-EOL care, defined as the occurrence of ≥1 chemotherapy session <14 days from death, receiving care in an intensive care unit ≥1 time, >1 emergency room admission, and >1 hospitalization in an acute care unit in the last 30 days of life.
    Results: The study included 1899 individuals from 345 hospitals; 61.4% experienced HI-EOL care. HI-EOL was increased with social disadvantage (adjusted odds ratio [AOR], 1.30; 95% confidence interval [CI], 1.03-1.65; P = .028), hematological malignancies (AOR, 2.09; 95% CI, 1.57-2.77; P < .001), complex chronic conditions (AOR, 1.60; 95% CI, 1.23-2.09; P = .001) and care delivered in a specialty center (AOR, 1.70; 95% CI, 1.22-2.36; P = .001). HI-EOL was reduced in cases of palliative care (AOR, 0.31; 95% CI, 0.24-0.41; P < .001).
    Conclusion: A majority of children, adolescents, and young adults experience HI-EOL care. Several features (eg, social disadvantage, cancer diagnosis, complex chronic conditions, and specialty center care) were associated with HI-EOL care. These findings should now be discussed with patients, families, and professionals to define the optimal EOL.
    MeSH term(s) Adolescent ; Adult ; Child ; Child, Preschool ; Databases, Factual ; Female ; Follow-Up Studies ; France/epidemiology ; Humans ; Infant ; Infant, Newborn ; Male ; Neoplasms/epidemiology ; Neoplasms/mortality ; Neoplasms/therapy ; Palliative Care/methods ; Palliative Care/statistics & numerical data ; Prognosis ; Retrospective Studies ; Survival Rate ; Terminal Care/methods ; Terminal Care/statistics & numerical data ; Young Adult
    Language English
    Publishing date 2019-03-26
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1429-1
    ISSN 1097-0142 ; 0008-543X ; 1934-662X
    ISSN (online) 1097-0142
    ISSN 0008-543X ; 1934-662X
    DOI 10.1002/cncr.32035
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.146: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Looking at the seemingly contradictory role of vinblastine in anaplastic large-cell lymphoma from a metronomic perspective.

    André, Nicolas / Pasquier, Eddy / Gentet, Jean Claude / Kamen, Barton A

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2011  Volume 29, Issue 4, Page(s) e90–1; author reply e92–3

    MeSH term(s) Angiogenesis Inhibitors/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Drug Administration Schedule ; Humans ; Lymphoma, Large-Cell, Anaplastic/drug therapy ; Lymphoma, Large-Cell, Anaplastic/immunology ; Lymphoma, Large-Cell, Anaplastic/pathology ; Treatment Outcome ; Tumor Escape/drug effects ; Vinblastine/administration & dosage
    Chemical Substances Angiogenesis Inhibitors ; Vinblastine (5V9KLZ54CY)
    Language English
    Publishing date 2011-02-01
    Publishing country United States
    Document type Comment ; Letter
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.2010.32.2883
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1847: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 650: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Medulloblastoma.

    Padovani, Laetitia / André, Nicolas / Gentet, Jean Claude / Muracciole, Xavier

    European journal of cancer (Oxford, England : 1990)

    2011  Volume 47 Suppl 3, Page(s) S338

    MeSH term(s) Age of Onset ; Cerebellar Neoplasms/classification ; Cerebellar Neoplasms/diagnosis ; Cerebellar Neoplasms/epidemiology ; Cerebellar Neoplasms/therapy ; Humans ; Medulloblastoma/classification ; Medulloblastoma/diagnosis ; Medulloblastoma/epidemiology ; Medulloblastoma/therapy ; Prognosis
    Language English
    Publishing date 2011-09
    Publishing country England
    Document type Journal Article
    ZDB-ID 82061-1
    ISSN 1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
    ISSN (online) 1879-0852
    ISSN 0277-5379 ; 0959-8049 ; 0964-1947
    DOI 10.1016/S0959-8049(11)70194-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 456: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 583: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Metronomic scheduling of anticancer agents for a refractory orbital pseudotumor in a child.

    Elhoudzi, Jamila / Rome, Angélique / Padovani, Laetitia / Gentet, Jean Claude / André, Nicolas

    Journal of pediatric hematology/oncology

    2013  Volume 35, Issue 8, Page(s) 632–633

    MeSH term(s) Administration, Metronomic ; Anti-Inflammatory Agents/therapeutic use ; Antineoplastic Agents/administration & dosage ; Celecoxib ; Child ; Cyclophosphamide/administration & dosage ; Humans ; Male ; Orbital Pseudotumor/drug therapy ; Prednisone/therapeutic use ; Pyrazoles/administration & dosage ; Sulfonamides/administration & dosage
    Chemical Substances Anti-Inflammatory Agents ; Antineoplastic Agents ; Pyrazoles ; Sulfonamides ; Cyclophosphamide (8N3DW7272P) ; Celecoxib (JCX84Q7J1L) ; Prednisone (VB0R961HZT)
    Language English
    Publishing date 2013-11
    Publishing country United States
    Document type Case Reports ; Letter
    ZDB-ID 1231152-2
    ISSN 1536-3678 ; 1077-4114 ; 0192-8562
    ISSN (online) 1536-3678
    ISSN 1077-4114 ; 0192-8562
    DOI 10.1097/MPH.0b013e3182707c00
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1537: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Recurrent extraneural sonic hedgehog medulloblastoma exhibiting sustained response to vismodegib and temozolomide monotherapies and inter-metastatic molecular heterogeneity at progression.

    Petrirena, Gregorio J / Masliah-Planchon, Julien / Sala, Quentin / Pourroy, Bertrand / Frappaz, Didier / Tabouret, Emeline / Graillon, Thomas / Gentet, Jean-Claude / Delattre, Olivier / Chinot, Olivier / Padovani, Laetitia

    Oncotarget

    2018  Volume 9, Issue 11, Page(s) 10175–10183

    Abstract: Background: Response to targeting and non-targeting agents is variable and molecular information remains poorly described in patients with recurrent sonic-hedgehog-driven medulloblastoma (SHH-MB).: Materials and methods: Clinical and PET/CT findings ... ...

    Abstract Background: Response to targeting and non-targeting agents is variable and molecular information remains poorly described in patients with recurrent sonic-hedgehog-driven medulloblastoma (SHH-MB).
    Materials and methods: Clinical and PET/CT findings during treatment with successive hedgehog antagonists and temozolomide monotherapies are described in a heavily pre-treated patient with recurrent extraneural metastases from
    Results: Sustained clinical/metabolic response was obtained to vi
    Conclusions: This is the first clinical report of recurrent extraneural
    Language English
    Publishing date 2018-01-03
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2560162-3
    ISSN 1949-2553 ; 1949-2553
    ISSN (online) 1949-2553
    ISSN 1949-2553
    DOI 10.18632/oncotarget.23699
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top